High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies

by Othman Al-Sawaf
Published 2024-03-01

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT...

by Othman Al-Sawaf, Min-Hua Jen, Lisa Hess, Jiewen Zhang, Benjamin Goebel, John Pagel, Toby Eyre
Published 2023-08-01

Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison

by Othman Al-Sawaf, Min-Hua Jen, Lisa M Hess, Jiewen Zhang, Benjamin Goebel, John M. Pagel, Sarang Abhyankar, Matthew S. Davids, Toby A. Eyre
Published 2023-11-01

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia

by Othman Al-Sawaf, Carmen Diana Herling, Udo Holtick, Christoph Scheid, Paula Cramer, Stephanie Sasse, Bastian von Tresckow, Armin Tuchscherer, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Lukas P. Frenzel
Published 2019-05-01

A novel laser-Doppler flowmetry assisted murine model of acute hindlimb ischemia-reperfusion for free flap research.

by Tolga Taha Sönmez, Othman Al-Sawaf, Gerald Brandacher, Isabella Kanzler, Nancy Tuchscheerer, Mersedeh Tohidnezhad, Anastasios Kanatas, Matthias Knobe, Athanassios Fragoulis, René Tolba, David Mitchell, Thomas Pufe, Christoph Jan Wruck, Frank Hölzle, Elisa Anamaria Liehn
Published 2013-01-01

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BI...

by Deyan Yosifov, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Billy Jebaraj, Daniel Mertens, Matthias Ritgen, Anke Schilhabel, Karl-Anton Kreuzer, Anna Maria Fink, Othman Al-Sawaf, Petra Langerbeins, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer, Paula Cramer, Eugen Tausch
Published 2023-08-01

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

by Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivcheva, Carsten Niemann, Anthony Schwarer, Javier Loscertales Pueyo, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Eva Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Published 2023-08-01

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CO...

by Petra Langerbeins, Sandra Robrecht, Pascal Nieper, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Christof Schneider, Lothar Müller, Michael Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Published 2023-08-01

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial

by Paula Cramer, Julia v. Tresckow, Sandra Robrecht, Jasmin Bahlo, Moritz Fürstenau, Petra Langerbeins, Natali Pflug, Othman Al-Sawaf, Werner J. Heinz, Ursula Vehling-Kaiser, Jan Dürig, Eugen Tausch, Manfred Hensel, Stephanie Sasse, Anna-Maria Fink, Kirsten Fischer, Karl-Anton Kreuzer, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Published 2020-02-01

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymph...

by Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Published 2023-10-01

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

by Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Published 2023-04-01